Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177 vipivotide tetraxetan for recurrent or metastatic salivary gland adenoid cystic carcinoma
2023-504699-73-00Phase 2Completed
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Sep 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in salivary gland adenoid cystic carcinoma (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Safety and tolerability. Started Sep 2023; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
salivary gland adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2023-504699-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504699-73-00.